Ignite Creation Date:
2025-12-24 @ 3:55 PM
Ignite Modification Date:
2026-01-20 @ 8:48 AM
Study NCT ID:
NCT03007992
Status:
COMPLETED
Last Update Posted:
2019-08-12
First Post:
2016-12-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer
Sponsor:
Johannes Gutenberg University Mainz
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
2015-007
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |